research Ruxolitinib Found to Cause Eyelash Growth: A Case Report
Ruxolitinib treatment may cause eyelash growth.
Search
for
Sort by
Research
60-90 / 1000+ results research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
research SnapshotDx Quiz: April 2022
Discoid Lupus Erythematosus causes scalp plaques that can lead to hair loss, and antimalarial drugs are effective treatments.
research Drug Repositioning Approach to Target Viral and Host Cells for COVID-19 Treatment: A Review of In Vivo Experiments and Clinical Studies
Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry About?
People with alopecia areata may have a higher risk of blood clots.
research Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
Ruxolitinib helped a man regrow his beard after years of hair loss.
research Alopecia in General Medicine
The document concludes that diagnosing and treating hair loss is complex and requires understanding its psychological effects and underlying causes, while also calling for more research and new treatments.
research Baricitinib: A Review in Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
research Efficacy of JAK 1/2 Inhibition in the Treatment of Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus
Baricitinib might help treat hair loss in lupus patients, but more research is needed.
research An Overview of Alopecia Areata: Etiopathogenesis, Diagnosis, and Management
Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
research Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.
research Brazilian Experience of Treating Alopecia Universalis with Novel Antirheumatic Therapy Tofacitinib: A Case Series
Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Alopecia Areata: Multifactorial Disease Involving Genetic, Environmental, and Autoimmune Factors
Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
research Drug Armamentarium for Alopecia Areata
No cure exists for alopecia areata, and treatments are personalized.
research Treating Alopecia Areata: Current Practices Versus New Directions
New treatments like JAK inhibitors show promise for reversing alopecia areata.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Treatment of Pediatric Alopecia Areata: A Systematic Review
Topical corticosteroids are the best initial treatment for children's alopecia areata.
research Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.